In terms of disease status, among the SMARCA4-mutated group, 13 patients (68.4%) were initially diagnosed with metastatic disease, 2 patients (10.5%) developed metastases following progression after preoperative therapy, and 4 patients (21.1%) had recurrent metastatic disease after undergoing radical surgery. Here, SMARCA4 is linked to metastatic neoplasm.